Eric S. Lander
Director (Departed Administration)
Estimated Net Worth
- $45.5 M - $154.1 M
Salary
- Unknown
Employment
- 01/20/2021 - 02/18/2022
Departed Administration
- Yes
Financial Disclosure Details - OGE Form 278e (01/21/2021)
Positions Held Outside United States Government
# | Organization | City | Position | To |
|---|---|---|---|---|
1 | Cambridge, Massachusetts | CEO, President, Director, and Professor | Present | |
2 | Cambridge, Massachusetts | Professor | Present | |
3 | Cambridge, Massachusetts | Professor | Present | |
4 | New York, New York | Member, Board of Directors | Present | |
5 | Cambridge, Massachusetts | Member, Board of Directors | Present | |
6 | Washington DC, District of Columbia | Member, Board of Directors | 12/2020 | |
7 | Cambridge, Massachusetts | Member, Board of Directors | Present | |
8 | Cambridge, Massachusetts | Member, Board of Directors | 5/2020 | |
9 | Boston, Massachusetts | Scientific Advisor | Present | |
10 | Boston, Massachusetts | Scientific Advisor | Present |
Employment Assets & Income and Retirement Accounts
# | Description | Value | Income Type | Income Amount |
|---|---|---|---|---|
1 | Codiak Biosciences (CDAK) common stock | $5,000,001 - $25,000,000 | None (or less than $201) | |
2 | Codiak Biosciences (CDAK) vested stock options (value not readily ascertainable); 19,188 vested shares, strike $3.29, expire 2/19/2026; 8,634 vested shares, strike $10.17, expire 2/1/2028 | None (or less than $201) | ||
3 | Codiak Biosciences (CDAK) stock options (value not readily ascertainable); 2,879 unvested shares, strike $10.17, expire 2/1/2028; 10,000 unvested shares, strike $15.00, expire 10/07/2030 | None (or less than $201) | ||
4 | Broad Institute of MIT and Harvard | Salary | $1,407,115 | |
5 | Codiak Biosciences | Director Fees | $73,750 | |
6 | BioNTech SE (BNTX). Formerly restricted shares of Neon Therapeutics (NTGN). | $500,001 - $1,000,000 | None (or less than $201) | |
7 | Neon Therapeutics | Director Fees | $83,214 | |
8 | The Broad Institute, Inc. 457(b) Plan | |||
8.1 | Fidelity Freedom 2025 K Shares | $100,001 - $250,000 | None (or less than $201) | |
9 | HARVARD UNIVERSITY TAX-DEFERRED ANNUITY PLAN |
Employment Agreements and Arrangements
# | Employer Or Party | City | Status And Terms | Date |
|---|---|---|---|---|
1 | Cambridge, Massachusetts | I will take an unpaid, two-year leave of absence consistent with Harvard and MIT policies. I have the right to continue to participate in my health plan provided that I pay both the employer and employee contributions. Extension of this leave of absence beyond two academic years is only possible in extraordinary circumstances and requires approval of the MIT Provost and the Broad Institute Board of Directors. | 1/2021 | |
2 | Cambridge, Massachusetts | I will take an unpaid, two-year leave of absence consistent with MIT policies. Extension of this beyond two academic years is only possible in extraordinary circumstances and requires approval of the Provost. | 1/2021 | |
3 | Cambridge, Massachusetts | I will take an unpaid, two-year leave of absence consistent with Harvard policies. The leave of absence cannot be extended further under any circumstances. | 1/2021 | |
4 | Cambridge, Massachusetts | Grant dated 2/19/2016: 19,188 shares at an exercise price of $3.29 per share. Vest 25% on first anniversary, 6.25% every quarter thereafter for 3 years. Expire 10 years from grant date, 2/19/2026. | 8/2015 | |
Grant dated 2/1/2018: 11,513 shares at an exercise price of $10.17 per share. Vest 25% on first anniversary, 6.25% every quarter thereafter for 3 years. Expire 10 years from grant date, 2/1/2028. | ||||
Grant dated 10/20/2020: 10,000 shares at an exercise price of $15.00 per share. Vest 100% on first anniversary. Expire 10 years from grant date, 10/20/2030. | ||||
I will exercise and sell vested options. I will forfeit all unvested stock options. | ||||
5 | Cambridge, Massachusetts | I will continue to participate in this defined contribution plan. The plan sponsor will not make contributions while I am on an unpaid leave of absence during my government service | 12/2017 | |
6 | Cambridge, Massachusetts | I will continue to participate in this defined contribution plan. The plan sponsor ceased making contributions upon my separation. | 10/1989 | |
7 | Cambridge, Massachusetts | I will continue to participate in this defined contribution plan. The plan sponsor ceased making contributions upon my separation. | 2/1992 |
Sources of Compensation Exceeding $5,000 in a Year
# | Source | City | Duties |
|---|---|---|---|
1 | Cambridge, Massachusetts | CEO, President, Director and Faculty Member | |
2 | Cambridge, Massachusetts | Member, Board of Directors (ended in 2020) | |
3 | Cambridge, Massachusetts | Member, Board of Directors | |
4 | Boston, Massachusetts | Member, Scientific Advisory Board | |
5 | Boston, Massachusetts | Member, Scientific Advisory Board | |
6 | Karnataka, India, Outside U.S. | Served on committee to select winner of the Infosys Prize; received honorarium; donated to charity. |
Spouse's Employment Assets & Income and Retirement Accounts
# | Description | Value | Type | Amount |
|---|---|---|---|---|
1 | IRA #1 | |||
1.1 | Old Westbury Fixed Income Fund | $100,001 - $250,000 | $1,001 - $2,500 | |
1.2 | Old Westbury Credit Income Fund | $15,001 - $50,000 | $1,001 - $2,500 | |
1.3 | Old Westbury Large Cap Strategies Fund | $500,001 - $1,000,000 | $1,001 - $2,500 | |
1.4 | Old Westbury All Cap Core Fund | $250,001 - $500,000 | $201 - $1,000 | |
1.5 | Old Westbury Small & Mid Cap Strategies Fund (OWSMX) | $250,001 - $500,000 | $201 - $1,000 | |
1.6 | Old Westbury Multi Asset Opportunities Fund | $15,001 - $50,000 | $201 - $1,000 |
Other Assets and Income
# | Description | Value | Type | Amount |
|---|---|---|---|---|
1 | Old Westbury Large Cap Strategies Fund (OWLSX) | $5,000,001 - $25,000,000 | $15,001 - $50,000 | |
2 | Old Westbury Small & Mid Cap Strategies Fund (OWSMX) | $1,000,001 - $5,000,000 | $2,501 - $5,000 | |
3 | Old Westbury All Cap Core Fund (OWACX) | $250,001 - $500,000 | None (or less than $201) | |
4 | Old Westbury Credit Income Fund (OWCIX) | $500,001 - $1,000,000 | $15,001 - $50,000 | |
5 | U.S. brokerage (cash) | $15,001 - $50,000 | Interest | None (or less than $201) |
6 | Univ of Texas bond | $250,001 - $500,000 | Interest | None (or less than $201) |
7 | U.S. brokerage (cash) | $100,001 - $250,000 | Interest | None (or less than $201) |
8 | Texas State bond | $100,001 - $250,000 | Interest | None (or less than $201) |
9 | Hampton Roads VA bond | $100,001 - $250,000 | Interest | None (or less than $201) |
10 | US Treasury Notes | $500,001 - $1,000,000 | Interest Capital Gains | $50,001 - $100,000 |
Transactions
# | Description | Type | Date | Amount |
|---|---|---|---|---|
Nothing reported in this section | ||||
Liabilities
# | Creditor | Amount | Incurred | Term |
|---|---|---|---|---|
1 | Cambridge Trust | $100,001 - $250,000 | 2000 | 30 years |
2 | 5TH AVE REAL ASSETS 3 T1 Fund | $100,001 - $250,000 | 2015 | On demand |
Gifts and Travel Reimbursements
# | Source Name | City | Description | Value |
|---|---|---|---|---|
Nothing reported in this section | ||||
Endnotes
Section | # | Description |
|---|---|---|
2 | 5 | $9,750 of the amount reported was received subsequent to filing the report. |
2 | 6 | Shares acquired via corporate action. BioNTech SE (BNTX) acquired Neon Therapeutics (NTGN) |
2 | 17 | Served on committee to select winner of the Infosys Prize; honorarium donated to charity. |
2 | 23 | Equity distributed in-kind is reported separately on this report. |
2 | 23.1.1 | Corvia Medical Inc. (medical devices); NinePoint Medical, Inc. (medical devices); Sensen Bio, Inc (therapeutics); Seventh Sense Biosystems Inc. (blood collection technology). |
2 | 23.2 | See holdings in endnote to line 23.1.1. Equity distributed in-kind is reported separately on this report. |
2 | 24 | Equity distributed in-kind is reported separately on this report. |
2 | 24.1.1 | Alcresta Therapeutics, Inc. (enzyme based products); Allena Pharmaceuticals, Inc. (ALNA); Jounce Therapeutics, Inc. (JNCE); Kibur Medical, Inc.(Medical Devices); PanOptica, Inc. (biopharmaceutical); Revolution Medicines, Inc. (RVMD) |
2 | 24.2 | See holdings in Endnote to line 24.1.1. Equity distributed in-kind is reported separately on this report. |
2 | 25 | Equity distributed in-kind is reported separately on this report. |
Do you have information about Eric S. Lander that is missing from this database?
Drop us a line at [email protected].